Changes in N-terminal pro-B-type natriuretic peptide and incidence of diabetes: The Multi-Ethnic Study of Atherosclerosis (MESA)

Diabetes and Metabolism

Volumn 41, Issue 5, 2015, Pages 378-386

  Sanchez, O A ^a   Duprez, D A ^b   Bahrami, H ^c   Peralta, C A ^d   Daniels, L B ^e   Lima, J A ^f   Maisel, A ^g   Folsom, A R ^a   Jacobs, D R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c STANFORD UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Change; Diabetes; Incidence; MESA study; Natriuretic peptides; NT proBNP

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; BRAIN NATRIURETIC PEPTIDE; IL6 PROTEIN, HUMAN; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; VERY ELDERLY; ASYMPTOMATIC DISEASES; ATHEROSCLEROSIS; BLOOD; COHORT ANALYSIS; DIABETES MELLITUS, TYPE 2; IMMUNOLOGY; MIDDLE AGED; MINNESOTA; PATHOPHYSIOLOGY; POISSON DISTRIBUTION; RISK; UPREGULATION;

AGED; AGED, 80 AND OVER; ASYMPTOMATIC DISEASES; ATHEROSCLEROSIS; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INTERLEUKIN-6; MALE; MIDDLE AGED; MINNESOTA; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; POISSON DISTRIBUTION; RISK; UP-REGULATION;

EID: 84947032921     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2015.04.005     Document Type: Article

References (29)

1. Everett B.M., Cook N.R., Chasman D.I., Magnone M.C., Bobadilla M., Rifai N., et al. Prospective evaluation of B-type natriuretic peptide concentrations and the risk of type 2 diabetes in women. Clin Chem 2013, 59:557-565. [Epub 2013/01/05].
2. Pfister R., Sharp S., Luben R., Welsh P., Barroso I., Salomaa V., et al. Mendelian randomization study of B-type natriuretic peptide and type 2 diabetes: evidence of causal association from population studies. PLoS Med 2011, 8:e1001112. [Epub 2011/11/01].
3. Magnusson M., Jujic A., Hedblad B., Engstrom G., Persson M., Struck J., et al. Low plasma level of atrial natriuretic peptide predicts development of diabetes: the prospective Malmo Diet and Cancer Study. J Clin Endocrinol Metab 2012, 97:638-645. [Epub 2011/11/25].
4. Lazo M., Young J.H., Brancati F.L., Coresh J., Whelton S., Ndumele C.E., et al. NH2-terminal pro-brain natriuretic peptide and risk of diabetes. Diabetes 2013, 62:3189-3193. [Epub 2013/06/05].
5. Sanchez O.A., Duprez D.A., Bahrami H., Daniels L.B., Folsom A.R., Lima J.A., et al. The associations between metabolic variables and NT-proBNP are blunted at pathological ranges: the Multi-Ethnic Study of Atherosclerosis. Metabolism 2014, 63:475-483. [Epub 2014/01/07].
6. Eggers K.M., Venge P., Lind L. Prognostic usefulness of the change in N-terminal pro B-type natriuretic peptide levels to predict mortality in a single community cohort aged≥70years. Am J Cardiol 2013, 111:131-136. [Epub 2012/10/09].
7. Wu A.H. Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results. Am Heart J 2006, 152:828-834. [Epub 2006/10/31].
8. Bild D.E., Bluemke D.A., Burke G.L., Detrano R., Diez Roux A.V., Folsom A.R., et al. Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol 2002, 156:871-881. [Epub 2002/10/25].
9. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419. [Epub 1985/07/01].
10. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502. [Epub 1972/06/01].
11. Karl J., Borgya A., Gallusser A., Huber E., Krueger K., Rollinger W., et al. Development of a novel. N-terminal-proBNP (NT-proBNP) assay with a low detection limit. Scand J Clin Lab Invest Suppl 1999, 230:177-181. [Epub 1999/07/02].
12. Mueller T., Gegenhuber A., Poelz W., Haltmayer M. Comparison of the Biomedica NT-proBNP enzyme immunoassay and the Roche NT-proBNP chemiluminescence immunoassay: implications for the prediction of symptomatic and asymptomatic structural heart disease. Clin Chem 2003, 49(6 Pt 1):976-979. [Epub 2003/05/27].
13. Peralta C.A., Katz R., Shlipak M., Dubin R., DeBoer I., Jenny N., et al. Kidney function decline in the elderly: impact of lipoprotein-associated phospholipase A(2). Am J Nephrol 2011, 34:512-518. [Epub 2011/11/08].
14. Peralta C.A., Jacobs D.R., Katz R., Ix J.H., Madero M., Duprez D.A., et al. Association of pulse pressure, arterial elasticity, and endothelial function with kidney function decline among adults with estimated GFR >60mL/min/1.73m(2): the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis 2012, 59:41-49. [Epub 2011/10/18].
15. Bertoni A.G., Whitt-Glover M.C., Chung H., Le K.Y., Barr R.G., Mahesh M., et al. The association between physical activity and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol 2009, 169:444-454. [Epub 2008/12/17].
16. Sharrett A.R., Ding J., Criqui M.H., Saad M.F., Liu K., Polak J.F., et al. Smoking, diabetes, and blood cholesterol differ in their associations with subclinical atherosclerosis: the Multiethnic Study of Atherosclerosis (MESA). Atherosclerosis 2006, 186:441-447.
17. Agatston A.S., Janowitz W.R., Hildner F.J., Zusmer N.R., Viamonte M., Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990, 15:827-832. [Epub 1990/03/15].
18. Natori S., Lai S., Finn J.P., Gomes A.S., Hundley W.G., Jerosch-Herold M., et al. Cardiovascular function in multi-ethnic study of atherosclerosis: normal values by age, sex, and ethnicity. AJR Am J Roentgenol 2006, 186(6 Suppl. 2):S357-S365. [Epub 2006/05/23].
19. Marz W., Tiran B., Seelhorst U., Wellnitz B., Bauersachs J., Winkelmann B.R., et al. N-terminal pro-B-type natriuretic peptide predicts total and cardiovascular mortality in individuals with or without stable coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health Study. Clin Chem 2007, 53:1075-1083. [Epub 2007/04/21].
20. Sanchez O.A., Jacob D.R., Bahrami H., Peralta C.A., Daniels L.B., Lima J.A., et al. Increasing aminoterminal-pro-B-type natriuretic peptide precedes the development of arterial hypertension: themultiethnic study of atherosclerosis. J Hypertens 2015, 33.
21. Cheng S., Fox C.S., Larson M.G., Massaro J.M., McCabe E.L., Khan A.M., et al. Relation of visceral adiposity to circulating natriuretic peptides in ambulatory individuals. Am J Cardiol 2011, 108:979-984. [Epub 2011/08/05].
22. Horwich T.B., Hamilton M.A., Fonarow G.C. B-type natriuretic peptide levels in obese patients with advanced heart failure. J Am Coll Cardiol 2006, 47:85-90. [Epub 2006/01/03].
23. Neeland I.J., Winders B.R., Ayers C.R., Das S.R., Chang A.Y., Berry J.D., et al. Higher natriuretic peptide levels associate with a favorable adipose tissue distribution profile. J Am Coll Cardiol 2013, 62:752-760. [Epub 2013/04/23].
24. Clerico A., Vittorini S., Passino C. Circulating forms of the B-type natriuretic peptide prohormone: pathophysiologic and clinical considerations. Adv Clin Chem 2012, 58:31-44.
25. Potter L.R., Garbers D.L. Dephosphorylation of the guanylyl cyclase-A receptor causes desensitization. J Biol Chem 1992, 267:14531-14534. [Epub 1992/07/25].
26. Halbirk M., Norrelund H., Moller N., Schmitz O., Botker H.E., Wiggers H. Short-term changes in circulating insulin and free fatty acids affect Nt-pro-BNP levels in heart failure patients. Int J Cardiol 2010, 144(1):140-142. [Epub 2009/01/30].
27. Heinisch B.B., Vila G., Resl M., Riedl M., Dieplinger B., Mueller T., et al. B-type natriuretic peptide (BNP) affects the initial response to intravenous glucose: a randomised placebo-controlled cross-over study in healthy men. Diabetologia 2012, 55:1400-1405. [Epub 2011/12/14].
28. O'Hanlon R., O'Shea P., Ledwidge M., O'Loughlin C., Lange S., Conlon C., et al. The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients. J Card Fail 2007, 13:50-55. [Epub 2007/03/07].
29. Dessi-Fulgheri P., Sarzani R., Rappelli A. Role of the natriuretic peptide system in lipogenesis/lipolysis. Nutr Metab Cardiovasc Dis 2003, 13:244-249. [Epub 2003/12/03].